| MRSN |
Mersana Therapeutics, Inc. |
Alleva Lawrence M |
Director
|
2026-01-06 |
D - D |
181 |
0.00 |
0.00 |
0 |
| MRSN |
Mersana Therapeutics, Inc. |
Alleva Lawrence M |
Director
|
2026-01-06 |
D - D |
734 |
0.00 |
0.00 |
0 |
| MRSN |
Mersana Therapeutics, Inc. |
Alleva Lawrence M |
Director
|
2026-01-06 |
D - D |
215 |
0.00 |
0.00 |
0 |
| MRSN |
Mersana Therapeutics, Inc. |
Alleva Lawrence M |
Director
|
2026-01-06 |
D - D |
561 |
0.00 |
0.00 |
0 |
| MRSN |
Mersana Therapeutics, Inc. |
Alleva Lawrence M |
Director
|
2026-01-06 |
D - D |
310 |
0.00 |
0.00 |
0 |
| MRSN |
Mersana Therapeutics, Inc. |
Alleva Lawrence M |
Director
|
2026-01-06 |
D - D |
159 |
0.00 |
0.00 |
0 |
| MRSN |
Mersana Therapeutics, Inc. |
Alleva Lawrence M |
Director
|
2026-01-06 |
D - D |
2,200 |
0.00 |
0.00 |
0 |
| MRSN |
Mersana Therapeutics, Inc. |
Alleva Lawrence M |
Director
|
2026-01-06 |
D - D |
358 |
0.00 |
0.00 |
0 |
| MRSN |
Mersana Therapeutics, Inc. |
Alleva Lawrence M |
Director
|
2026-01-06 |
D - D |
384 |
0.00 |
0.00 |
0 |
| MRSN |
Mersana Therapeutics, Inc. |
Alleva Lawrence M |
Director
|
2026-01-06 |
D - D |
500 |
0.00 |
0.00 |
0 |
| NAVN |
Navan, Inc. |
AH Equity Partners V (Parallel), L.L.C. |
10% Owner
|
2026-01-06 |
P - A |
308,188 |
16.74 |
5,159,067.12 |
8,300,455 |
| NAVN |
Navan, Inc. |
AH Equity Partners V (Parallel), L.L.C. |
10% Owner
|
2026-01-06 |
P - A |
308,188 |
16.74 |
5,159,067.12 |
8,300,455 |
| NAVN |
Navan, Inc. |
AH Equity Partners V (Parallel), L.L.C. |
10% Owner
|
2026-01-06 |
P - A |
308,188 |
16.74 |
5,159,067.12 |
8,300,455 |
| NAVN |
Navan, Inc. |
AH Equity Partners V (Parallel), L.L.C. |
10% Owner
|
2026-01-06 |
P - A |
308,188 |
16.74 |
5,159,067.12 |
8,300,455 |
| NAVN |
Navan, Inc. |
Andreessen Marc L |
10% Owner
|
2026-01-06 |
P - A |
308,188 |
16.74 |
5,159,067.12 |
8,300,455 |
| NAVN |
Navan, Inc. |
Andreessen Marc L |
10% Owner
|
2026-01-06 |
P - A |
308,188 |
16.74 |
5,159,067.12 |
8,300,455 |
| NAVN |
Navan, Inc. |
Andreessen Marc L |
10% Owner
|
2026-01-06 |
P - A |
308,188 |
16.74 |
5,159,067.12 |
8,300,455 |
| NAVN |
Navan, Inc. |
Andreessen Marc L |
10% Owner
|
2026-01-06 |
P - A |
308,188 |
16.74 |
5,159,067.12 |
8,300,455 |
| NAVN |
Navan, Inc. |
Andreessen Marc L |
10% Owner
|
2026-01-06 |
P - A |
308,188 |
16.74 |
5,159,067.12 |
8,300,455 |
| NAVN |
Navan, Inc. |
Andreessen Marc L |
10% Owner
|
2026-01-06 |
P - A |
308,188 |
16.74 |
5,159,067.12 |
8,300,455 |
| NAVN |
Navan, Inc. |
CLF Partners, LP |
10% Owner
|
2026-01-06 |
P - A |
308,188 |
16.74 |
5,159,067.12 |
8,300,455 |
| NAVN |
Navan, Inc. |
CLF Partners, LP |
10% Owner
|
2026-01-06 |
P - A |
308,188 |
16.74 |
5,159,067.12 |
8,300,455 |
| NAVN |
Navan, Inc. |
Andreessen Marc L |
10% Owner
|
2026-01-06 |
P - A |
308,188 |
16.74 |
5,159,067.12 |
8,300,455 |
| APGE |
Apogee Therapeutics, Inc. |
Henderson Jane |
Officer
|
2026-01-06 |
S - D |
2,000 |
80.00 |
160,000.00 |
185,371 |
| ACLX |
Arcellx, Inc. |
Gilson Michelle |
|
2026-01-06 |
M - A |
20,530 |
0.00 |
0.00 |
64,832 |